| Dr Trevor B Emory, MD | |
|
333 Borthwick Ave, Portsmouth, NH 03801-7128 | |
| (603) 436-5110 | |
| Not Available |
| Full Name | Dr Trevor B Emory |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Experience | 17 Years |
| Location | 333 Borthwick Ave, Portsmouth, New Hampshire |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1326261611 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | 15216 (New Hampshire) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Portsmouth Regional Hospital | Portsmouth, NH | Hospital |
| Frisbie Memorial Hospital | Rochester, NH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Portsmouth Anesthesia Associates Pa | 6002855327 | 44 |
News Archive
Health Care REIT, Inc. announced that it intends to offer, subject to market and other conditions, 7,000,000 shares of its common stock. Health Care REIT intends to grant the underwriters a 30-day option to purchase up to an additional 1,050,000 shares to cover over-allotments, if any. The shares of common stock will be registered under Health Care REIT's existing shelf registration statement on file with the Securities and Exchange Commission.
Pro-Pharmaceuticals, Inc. today announced that it has changed its name to Galectin Therapeutics Inc. to more accurately reflect the Company's core expertise in galectin science and its leading platform for the creation of galectin inhibitors to treat serious diseases including fibrosis and cancer.
A new antibody-drug compound shrank or halted the growth of metastatic breast tumors in almost half of a group of patients whose HER2-positive cancer had become resistant to standard therapies, according to early data from a multicenter Phase 2 clinical trial led by a Dana-Farber Cancer Institute researcher.
Phenomenex Inc., a global leader in the research and manufacture of advanced technologies for the separation sciences, announces the addition of over 1,700 new chiral HPLC/SFC applications to its online resource, including more than 400 new SFC (supercritical fluid chromatography) methods. Phenomenex's extensive chiral application database is unique in the industry, particularly with the addition of the SFC methods, which were developed in collaboration with the Department of Analytical Chemistry and Pharmaceutical Technology, Vrije Universiteit Brussel, Brussels, Belgium.
› Verified 7 days ago
| Entity Name | Portsmouth Anesthesia Associates Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1568584290 PECOS PAC ID: 6002855327 Enrollment ID: O20050427000080 |
News Archive
Health Care REIT, Inc. announced that it intends to offer, subject to market and other conditions, 7,000,000 shares of its common stock. Health Care REIT intends to grant the underwriters a 30-day option to purchase up to an additional 1,050,000 shares to cover over-allotments, if any. The shares of common stock will be registered under Health Care REIT's existing shelf registration statement on file with the Securities and Exchange Commission.
Pro-Pharmaceuticals, Inc. today announced that it has changed its name to Galectin Therapeutics Inc. to more accurately reflect the Company's core expertise in galectin science and its leading platform for the creation of galectin inhibitors to treat serious diseases including fibrosis and cancer.
A new antibody-drug compound shrank or halted the growth of metastatic breast tumors in almost half of a group of patients whose HER2-positive cancer had become resistant to standard therapies, according to early data from a multicenter Phase 2 clinical trial led by a Dana-Farber Cancer Institute researcher.
Phenomenex Inc., a global leader in the research and manufacture of advanced technologies for the separation sciences, announces the addition of over 1,700 new chiral HPLC/SFC applications to its online resource, including more than 400 new SFC (supercritical fluid chromatography) methods. Phenomenex's extensive chiral application database is unique in the industry, particularly with the addition of the SFC methods, which were developed in collaboration with the Department of Analytical Chemistry and Pharmaceutical Technology, Vrije Universiteit Brussel, Brussels, Belgium.
› Verified 7 days ago
| Entity Name | Stratham Anesthesia Associates Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1346480639 PECOS PAC ID: 7416007950 Enrollment ID: O20090604000241 |
News Archive
Health Care REIT, Inc. announced that it intends to offer, subject to market and other conditions, 7,000,000 shares of its common stock. Health Care REIT intends to grant the underwriters a 30-day option to purchase up to an additional 1,050,000 shares to cover over-allotments, if any. The shares of common stock will be registered under Health Care REIT's existing shelf registration statement on file with the Securities and Exchange Commission.
Pro-Pharmaceuticals, Inc. today announced that it has changed its name to Galectin Therapeutics Inc. to more accurately reflect the Company's core expertise in galectin science and its leading platform for the creation of galectin inhibitors to treat serious diseases including fibrosis and cancer.
A new antibody-drug compound shrank or halted the growth of metastatic breast tumors in almost half of a group of patients whose HER2-positive cancer had become resistant to standard therapies, according to early data from a multicenter Phase 2 clinical trial led by a Dana-Farber Cancer Institute researcher.
Phenomenex Inc., a global leader in the research and manufacture of advanced technologies for the separation sciences, announces the addition of over 1,700 new chiral HPLC/SFC applications to its online resource, including more than 400 new SFC (supercritical fluid chromatography) methods. Phenomenex's extensive chiral application database is unique in the industry, particularly with the addition of the SFC methods, which were developed in collaboration with the Department of Analytical Chemistry and Pharmaceutical Technology, Vrije Universiteit Brussel, Brussels, Belgium.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Trevor B Emory, MD 333 Borthwick Ave, Portsmouth, NH 03801-7128 Ph: (603) 436-5110 | Dr Trevor B Emory, MD 333 Borthwick Ave, Portsmouth, NH 03801-7128 Ph: (603) 436-5110 |
News Archive
Health Care REIT, Inc. announced that it intends to offer, subject to market and other conditions, 7,000,000 shares of its common stock. Health Care REIT intends to grant the underwriters a 30-day option to purchase up to an additional 1,050,000 shares to cover over-allotments, if any. The shares of common stock will be registered under Health Care REIT's existing shelf registration statement on file with the Securities and Exchange Commission.
Pro-Pharmaceuticals, Inc. today announced that it has changed its name to Galectin Therapeutics Inc. to more accurately reflect the Company's core expertise in galectin science and its leading platform for the creation of galectin inhibitors to treat serious diseases including fibrosis and cancer.
A new antibody-drug compound shrank or halted the growth of metastatic breast tumors in almost half of a group of patients whose HER2-positive cancer had become resistant to standard therapies, according to early data from a multicenter Phase 2 clinical trial led by a Dana-Farber Cancer Institute researcher.
Phenomenex Inc., a global leader in the research and manufacture of advanced technologies for the separation sciences, announces the addition of over 1,700 new chiral HPLC/SFC applications to its online resource, including more than 400 new SFC (supercritical fluid chromatography) methods. Phenomenex's extensive chiral application database is unique in the industry, particularly with the addition of the SFC methods, which were developed in collaboration with the Department of Analytical Chemistry and Pharmaceutical Technology, Vrije Universiteit Brussel, Brussels, Belgium.
› Verified 7 days ago
Olivera Janjic Quitkin, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 333 Borthwick Ave, Portsmouth Anesthesia Associates, Portsmouth, NH 03801 Phone: 603-436-5110 | |
Michael N Baker, M.D. Anesthesiology Medicare: Medicare Enrolled Practice Location: 100 Griffin Road, Suite B, Portsmouth, NH 03801 Phone: 603-431-8819 Fax: 603-427-2540 | |
Dr. Peter Chiayen Huang, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 333 Borthwick Ave, Portsmouth, NH 03801 Phone: 603-436-5110 | |
Dr. Andrew Joseph Kulesza, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 333 Borthwick Ave, Portsmouth, NH 03801 Phone: 603-436-5110 | |
Dr. Richard James Duffy, MD Anesthesiology Medicare: Medicare Enrolled Practice Location: 333 Borthwick Ave, Portsmouth, NH 03801 Phone: 603-436-5110 | |
Dr. Robert Lehn, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 14 Manchester Sq, Portsmouth, NH 03801 Phone: 603-766-8500 Fax: 603-766-8550 |